Literature DB >> 27431825

Effects of irreversible electroporation on cervical cancer cell lines in vitro.

Qin Qin1, Zheng-Ai Xiong1, Ying Liu2, Chen-Guo Yao3, Wei Zhou4, Yuan-Yuan Hua1, Zhi-Liang Wang1.   

Abstract

The effects of irreversible electroporation (IRE) on the proliferation, migration, invasion and adhesion of human cervical cancer cell lines HeLa and SiHa were investigated in the present study. HeLa and SiHa cells were divided into a treatment group and control group. The treatment group cells were exposed to electric pulses at 16 pulses, 1 Hz frequency for 100 µsec with 1,000 V/cm strength. Cellular proliferation was determined 24 h after treatment using a Cell Counting Kit‑8 (CCK‑8) assay and carboxyfluorescein diacetate‑succinimidyl ester (CFDA‑SE) labeling assay. The different phases of the cell cycle were detected using flow cytometry. Wound healing, Transwell invasion and Matrigel adhesion assays were performed to evaluate the migration, invasion and adhesion abilities of HeLa and SiHa cells. The expression levels of metastasis‑associated proteins were determined by western blot analysis. CCK‑8 and CFSE labeling assays indicated that the inhibition of cellular proliferation occurs in cells treated with IRE. Additionally, cell cycle progression was arrested at the G1/S phase. A western blot analysis indicated that the expression levels of p53 and p21 proteins were increased, whilst those of cyclin‑dependent kinase 2 (CDK2) and proliferating cell nuclear antigen (PCNA) proteins were decreased. However, wound healing, invasion and adhesion assays indicated that cellular migration, invasion and adhesion abilities were not significantly altered following exposure to IRE. IRE was not observed to promote the migration, invasion or adhesion capacity of HeLa and SiHa cells. However, IRE may inhibit the capacity of cells to proliferate and their progression through the cell cycle in vitro. Preliminary evidence suggests that the underlying mechanism involves increased expression levels of p53 and p21 and decreased expression levels of CDK2 and PCNA.

Entities:  

Mesh:

Year:  2016        PMID: 27431825     DOI: 10.3892/mmr.2016.5468

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  7 in total

1.  Dynamics of Cell Death After Conventional IRE and H-FIRE Treatments.

Authors:  Borja Mercadal; Natalie Beitel-White; Kenneth N Aycock; Quim Castellví; Rafael V Davalos; Antoni Ivorra
Journal:  Ann Biomed Eng       Date:  2020-02-05       Impact factor: 3.934

2.  Oxidative Effects during Irreversible Electroporation of Melanoma Cells-In Vitro Study.

Authors:  Wojciech Szlasa; Aleksander Kiełbik; Anna Szewczyk; Nina Rembiałkowska; Vitalij Novickij; Mounir Tarek; Jolanta Saczko; Julita Kulbacka
Journal:  Molecules       Date:  2020-12-31       Impact factor: 4.411

Review 3.  Electroporation and Electrochemotherapy in Gynecological and Breast Cancer Treatment.

Authors:  Zofia Łapińska; Urszula Szwedowicz; Anna Choromańska; Jolanta Saczko
Journal:  Molecules       Date:  2022-04-12       Impact factor: 4.927

4.  Electroporation Parameters for Human Cardiomyocyte Ablation In Vitro.

Authors:  Jara M Baena-Montes; Tony O'Halloran; Cormac Clarke; Kevin Donaghey; Eoghan Dunne; Martin O'Halloran; Leo R Quinlan
Journal:  J Cardiovasc Dev Dis       Date:  2022-07-28

5.  Establishing electroporation thresholds for targeted cell specific cardiac ablation in a 2D culture model.

Authors:  Sahar Avazzadeh; Mahshid H Dehkordi; Peter Owens; Amirhossein Jalali; Barry O'Brien; Ken Coffey; Martin O'Halloran; Howard O Fernhead; David Keane; Leo R Quinlan
Journal:  J Cardiovasc Electrophysiol       Date:  2022-08-16       Impact factor: 2.942

Review 6.  A Review on Differences in Effects on Normal and Malignant Cells and Tissues to Electroporation-Based Therapies: A Focus on Calcium Electroporation.

Authors:  Stine K Frandsen; Julie Gehl
Journal:  Technol Cancer Res Treat       Date:  2018-01-01

Review 7.  Chemical Enhancement of Irreversible Electroporation: A Review and Future Suggestions.

Authors:  Ying Chen; Michael A J Moser; Yigang Luo; Wenjun Zhang; Bing Zhang
Journal:  Technol Cancer Res Treat       Date:  2019-01-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.